Suppr超能文献

缩宫素与口服米索前列醇用于足月胎膜早破孕妇引产的随机临床试验。

Oxytocin Versus Oral Misoprostol for Induction of Labor in Pregnant Women with Term Prelabor Rupture of Membranes: a Randomized Clinical Trial.

机构信息

Department of Gynecology and Obstetrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

出版信息

Reprod Sci. 2023 Dec;30(12):3507-3514. doi: 10.1007/s43032-023-01290-0. Epub 2023 Jul 13.

Abstract

This study compares the effectiveness and safety of oxytocin infusion against oral misoprostol for inducing labour in pregnant women with term prelabor membrane rupture. We randomized 173 pregnant women presenting with term prelabor rupture of membranes (PROM) at Ain Shams University Maternity Hospital into Group A (underwent induction of labor (IOL) by 25μg misoprostol oral tablet every 4 h, for maximum 5 doses) and an identical Group B: (underwent IOL by oxytocin infusion according to the hospital protocol). Our primary outcome was rate of vaginal delivery within 24 h, while the secondary outcomes included the time till active phase, induction to delivery interval, maternal pyrexia, nausea and vomiting, fetal distress, Apgar score, birth weight, and neonatal intensive care unit admission. Both groups showed high rates of vaginal delivery (82.4% & 87.1% for misoprostol group and oxytocin group respectively) with no significant difference between the two groups (p=0.394). However, patients induced by misoprostol took significantly less time to reach active phase with a shorter induction to delivery interval as compared to patients induced with oxytocin. This difference was clear in multiparous women, but not observed in primiparous women when subgroup analysis was done. No significant difference was found as regards other outcomes. Our study showed that both oral misoprostol and oxytocin are effective and safe for IOL in patients with PROM, with shorter induction-delivery interval in patients induced by oral misoprostol, an effect that is clear in multiparous but not primiparous women. TRIAL REGISTRATION: NCT05215873, on 31/01/2022, "retrospectively registered".

摘要

这项研究比较了催产素输注与口服米索前列醇在足月胎膜早破孕妇引产中的效果和安全性。我们将 173 名在 Ain Shams 大学妇产医院出现足月胎膜早破(PROM)的孕妇随机分为 A 组(每 4 小时口服 25μg 米索前列醇片,最多 5 剂,进行引产)和 B 组(根据医院方案进行催产素输注进行引产)。我们的主要结局是 24 小时内阴道分娩率,次要结局包括活跃期时间、引产至分娩间隔、产妇发热、恶心呕吐、胎儿窘迫、阿普加评分、出生体重和新生儿重症监护病房入院率。两组阴道分娩率均较高(米索前列醇组和催产素组分别为 82.4%和 87.1%),两组间无显著差异(p=0.394)。然而,与催产素组相比,米索前列醇组患者达到活跃期的时间明显更短,引产至分娩的间隔更短。这种差异在经产妇中很明显,但在初产妇中进行亚组分析时并未观察到。其他结局无显著差异。我们的研究表明,口服米索前列醇和催产素对 PROM 患者的引产均有效且安全,口服米索前列醇组引产至分娩的间隔更短,这种作用在经产妇中明显,但在初产妇中不明显。

注册号

NCT05215873,于 2022 年 1 月 31 日进行“回顾性注册”。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4edd/10692250/14824776a5ae/43032_2023_1290_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验